stockrow
Friday 6 November 2026
Export SRPT’s income statement to Excel — free account
Sarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
17.71
0.14
+0.80%
Follow SRPT
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 4 | 6 | 3 |
+8 more TTM periods Free account |
| (8.05%) | (9.48%) | 4.91% | (53.47%) | ||
| (3.44%) | (3.98%) | 1.96% | (19.51%) | ||
ROIC |
(2.03%) | (5.64%) | (1.51%) | (42.46%) | |
Return on Tangible Assets |
(5.92%) | (6.68%) | 3.03% | (39.90%) | |
Average Days of Receivables |
68.88 | 69.66 | 65.98 | 66.12 | |
Free Cash Flow per Share |
1.67 | 0.71 | 1.03 | (3.15) | |
Free Cash Flow |
176.40 | 74.97 | 108.24 | (315.33) | |
Capital Expenditures |
(9.16) | (36.04) | (67.04) | (109.85) | |
| Other line items | |||||
Cash ROIC |
5.40% | 2.37% | 3.61% | (10.84%) | |
Accounts Receivable Turnover |
5.12 | 4.37 | 4.14 | 4.40 | |
Accounts Payable Turnover |
0.00 | 8.61 | 7.16 | 3.39 | |
Inventory Turnover |
0.00 | 0.85 | 0.83 | 1.01 | |
Average Days of Payables |
0.00 | 23.04 | 31.68 | 122.09 | |
Days of Inventory on Hand |
0.00 | 408.67 | 450.67 | 397.67 | |
Tax Rate |
(0.60) | 0.04 | 1.66 | 0.02 | |
Research and Development Expense of Revenue |
33.38% | 39.99% | 41.32% | 69.24% | |
Selling, General and Administrative Expense of Revenue |
23.69% | 22.12% | 21.38% | 22.37% | |
Share Based Compensation of Revenue |
5.65% | 5.00% | 5.10% | 5.61% | |
Operating CF/Net income |
(1.62) | (0.81) | 2.69 | 0.29 | |
Depreciation/Fixed assets |
0.00 | 0.13 | 0.12 | 0.11 | |
Capex/Depreciation |
0.00 | (0.86) | (1.63) | (2.80) | |
Revenue per Share |
18.47 | 18.73 | 20.80 | 21.96 | |
Operating CF per Share |
1.75 | 1.05 | 1.67 | (2.05) | |
Capex per Share |
(0.09) | (0.34) | (0.64) | (1.10) | |
Capex to Sales |
0.00 | 0.02 | 0.03 | 0.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026